




Belgian Cancer Registry

CANCER FACT SHEET 2022

BLADDER CANCER

ICD-10 C67



CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ($=200 \times 1.05$) and 255/100,000 over 5 years ($=200 \times (1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. For bladder cancer, stage IV means the cancer has spread to distant lymph nodes or other organs. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

- **Clinical stage:** Stage based on clinical examinations (e.g.: medical imaging, biopsies) to estimate the extent of the tumour. Clinical stage is established before the start of any treatment.
- **Pathological stage:** Stage based on pathological examinations of the tumour after surgery. **Pathological stage without neo-adjuvant therapy** is the pathological stage in the population that did not receive neo-adjuvant therapy prior to surgery. **Pathological stage after neo-adjuvant therapy** is the pathological stage in the population that did receive neo-adjuvant therapy prior to surgery. Pathological stage regardless of neo-adjuvant therapy is reported as (y)pStage.
- **Neo-adjuvant therapy (NAT):** Treatment (e.g.: chemotherapy/radiotherapy) given prior to surgery, with the goal to shrink the tumour before operating.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE	5
1.1. Bladder cancer incidence: by region	5
1.1.1. Bladder cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Bladder cancer incidence: by tumour stage	7
1.2.1. Bladder cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.2. Bladder cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	7
1.2.3. Bladder cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.3. Bladder cancer incidence: by tumour type	9
1.3.1. Bladder cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	9
2. CANCER INCIDENCE TRENDS	10
2.1. Bladder cancer incidence trends: by region	10
2.1.1. Bladder cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	10
2.1.2. Bladder cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	12
2.2. Bladder cancer incidence trends: by tumour stage	13
2.2.1. Bladder cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards...	13
2.3. Bladder cancer incidence trends: by age group	15
2.3.1. Bladder cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	15
2.3.2. Bladder cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	16
3. CANCER PREVALENCE	17
3.1. Bladder cancer prevalence: by region	17
3.1.1. Bladder cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	17
4. CANCER SURVIVAL.....	18
4.1. Bladder cancer survival: by region	18
4.1.1. Bladder cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022	18
4.2. Bladder cancer survival: by tumour stage	20
4.2.1. Bladder cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022.....	20
4.2.2. Bladder cancer survival by pathological stage ((y)pStage), and sex: number at risk and net survival probabilities, 2013-2022	21

4.2.3. Bladder cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022.....	22
5. CANCER SURVIVAL TRENDS.....	23
5.1. Bladder cancer survival trends: by tumour stage.....	23
5.1.1. Bladder cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022	23
6. CANCER MORTALITY.....	25
6.1. Bladder cancer mortality: by region.....	25
6.1.1. Bladder cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age- standardised mortality rates, 2021.....	25
7. CANCER MORTALITY TRENDS.....	27
7.1. Bladder cancer mortality trends: by region.....	27
7.1.1. Bladder cancer mortality* trends in males, by region: number of cancer deaths, crude and age- standardised mortality rates, including average annual percentage change, 2004-2021.....	27
7.1.2. Bladder cancer mortality* trends in females, by region: number of cancer deaths, crude and age- standardised mortality rates, including average annual percentage change, 2004-2021.....	29

1. CANCER INCIDENCE



1.1. Bladder cancer incidence: by region

1.1.1. Bladder cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	0	0	0	3	5	12	47	104	180	279	395	384	322	228	92	15	2,066	40.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[1.3]	[3.2]	[11.9]	[25.7]	[48.8]	[89.3]	[149.6]	[201.8]	[254.3]	[290.6]	[306.4]	[256.4]	[36.2]	(38.2; 41.7)
Brussels	0	0	0	0	0	0	0	0	1	3	5	11	7	15	37	20	22	16	7	1	145	41.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.2]	[6.9]	[12.4]	[31.7]	[25.0]	[70.8]	[224.0]	[164.3]	[272.4]	[314.5]	[322.9]	[187.6]	[24.2]	(34.4; 48.0)
Flanders	0	0	0	0	0	0	0	2	0	4	22	54	99	156	215	227	202	148	61	7	1,197	36.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.0]	[0.0]	[1.9]	[9.5]	[22.1]	[44.0]	[81.2]	[133.0]	[183.9]	[241.7]	[282.1]	[306.1]	[185.2]	[36.1]	(34.4; 38.6)
Wallonia	0	0	0	0	0	0	0	1	4	5	20	39	74	108	143	137	98	64	24	7	724	46.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[3.5]	[4.1]	[16.1]	[31.2]	[63.7]	[108.8]	[166.6]	[250.9]	[280.3]	[306.3]	[302.6]	[455.1]	[40.4]	(43.4; 50.3)
Females																						
Belgium	0	0	0	0	0	0	0	1	3	8	19	27	35	59	81	105	85	86	55	6	570	8.6
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.8]	[2.2]	[4.9]	[6.8]	[9.3]	[17.7]	[27.4]	[45.4]	[47.7]	[63.9]	[79.3]	[29.2]	[9.7]	(7.9; 9.3)
Brussels	0	0	0	0	0	0	0	1	0	0	1	3	4	3	5	8	4	9	5	1	44	8.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.1]	[0.0]	[0.0]	[2.7]	[8.9]	[13.4]	[12.0]	[23.4]	[46.4]	[30.7]	[89.5]	[86.6]	[48.5]	[7.1]	(5.8; 10.8)

Region	N [CR]																				ESR2013 (95%CI)		
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages	
Flanders	0	0	0	0	0	0	0	0	0	4	13	13	15	32	42	59	47	57	36	4	322	7.8	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.9]	[5.8]	[5.5]	[6.7]	[16.2]	[24.2]	[41.3]	[42.0]	[67.0]	[84.5]	[33.1]	[9.5]	(7.0; 8.7)
Wallonia	0	0	0	0	0	0	0	0	3	4	5	11	16	24	34	38	34	20	14	1	204	10.0	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.6]	[3.3]	[4.0]	[8.7]	[13.1]	[21.8]	[33.9]	[53.6]	[63.9]	[50.6]	[66.6]	[15.7]	[10.9]	(8.6; 11.4)

1.2. Bladder cancer incidence: by tumour stage

1.2.1. Bladder cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	55 [1.6]	322 [34.1]	355 [82.3]	732 [12.8]	14.0 (13.0; 15.1)	14 [0.4]	49 [4.9]	97 [15.3]	160 [2.7]	2.4 (2.0; 2.7)
II	43 [1.3]	196 [20.7]	270 [62.6]	509 [8.9]	9.9 (9.1; 10.8)	16 [0.5]	42 [4.2]	101 [15.9]	159 [2.7]	2.4 (2.0; 2.8)
III	18 [0.5]	72 [7.6]	99 [23.0]	189 [3.3]	3.7 (3.2; 4.2)	14 [0.4]	26 [2.6]	38 [6.0]	78 [1.3]	1.2 (0.9; 1.5)
IV	15 [0.4]	64 [6.8]	58 [13.5]	137 [2.4]	2.6 (2.2; 3.0)	6 [0.2]	22 [2.2]	29 [4.6]	57 [1.0]	0.9 (0.7; 1.1)
X/NA	40 [1.2]	200 [21.2]	259 [60.1]	499 [8.7]	9.7 (8.8; 10.5)	8 [0.2]	36 [3.6]	72 [11.4]	116 [2.0]	1.7 (1.4; 2.0)

1.2.2. Bladder cancer incidence by pathological stage ((y)pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

(y)pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	86 [2.6]	479 [50.7]	540 [125.2]	1,105 [19.4]	21.2 (20.0; 22.5)	20 [0.6]	76 [7.6]	136 [21.5]	232 [3.9]	3.5 (3.0; 3.9)
II	26 [0.8]	101 [10.7]	157 [36.4]	284 [5.0]	5.5 (4.9; 6.2)	7 [0.2]	19 [1.9]	55 [8.7]	81 [1.4]	1.2 (0.9; 1.5)
III	15 [0.4]	103 [10.9]	113 [26.2]	231 [4.0]	4.4 (3.9; 5.0)	14 [0.4]	35 [3.5]	43 [6.8]	92 [1.6]	1.5 (1.2; 1.8)
IV	4 [0.1]	19 [2.0]	19 [4.4]	42 [0.7]	0.8 (0.6; 1.1)	3 [0.1]	12 [1.2]	7 [1.1]	22 [0.4]	0.3 (0.2; 0.5)
X/NA	40 [1.2]	152 [16.1]	212 [49.2]	404 [7.1]	8.0 (7.2; 8.7)	14 [0.4]	33 [3.3]	96 [15.1]	143 [2.4]	2.1 (1.8; 2.5)

1.2.3. Bladder cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
I	88 [2.6]	480 [50.8]	549 [127.3]	1,117 [19.6]	21.5 (20.2; 22.7)	20 [0.6]	74 [7.4]	137 [21.6]	231 [3.9]	3.4 (3.0; 3.9)
II	41 [1.2]	184 [19.5]	255 [59.1]	480 [8.4]	9.4 (8.6; 10.3)	14 [0.4]	39 [3.9]	97 [15.3]	150 [2.6]	2.2 (1.9; 2.6)
III	22 [0.7]	105 [11.1]	141 [32.7]	268 [4.7]	5.2 (4.6; 5.8)	17 [0.5]	32 [3.2]	52 [8.2]	101 [1.7]	1.6 (1.3; 1.9)
IV	15 [0.4]	68 [7.2]	64 [14.8]	147 [2.6]	2.8 (2.3; 3.3)	7 [0.2]	25 [2.5]	32 [5.0]	64 [1.1]	1.0 (0.8; 1.3)
X/NA	5 [0.1]	17 [1.8]	32 [7.4]	54 [0.9]	1.1 (0.8; 1.4)	0 [0.0]	5 [0.5]	19 [3.0]	24 [0.4]	0.3 (0.2; 0.5)

1.3. Bladder cancer incidence: by tumour type

1.3.1. *Bladder cancer incidence by tumour type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022*

type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-59	60-74	75+	All ages		15-59	60-74	75+	All ages	
Urothelial cell carcinoma	160 [4.8]	823 [87.0]	982 [227.8]	1,965 [34.4]	37.9 (36.2; 39.6)	50 [1.5]	164 [16.3]	297 [46.9]	511 [8.7]	7.7 (7.0; 8.4)
Other	11 [0.3]	31 [3.3]	59 [13.7]	101 [1.8]	2.0 (1.6; 2.5)	8 [0.2]	11 [1.1]	40 [6.3]	59 [1.0]	0.9 (0.6; 1.1)

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
																					-0.4 (-1.9; 1.0)	2015-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Bladder cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	N	394	451	391	421	482	467	478	473	494	481	507	511	508	468	526	515	530	572	570		
	CR	7.4	8.5	7.3	7.8	8.9	8.5	8.6	8.5	8.8	8.5	8.9	9.0	8.9	8.1	9.1	8.9	9.1	9.8	9.7		
	ESR2013	7.3	8.4	7.2	7.5	8.5	8.1	8.3	8.1	8.3	7.8	8.2	8.2	8.1	7.4	8.3	8.0	8.3	8.8	8.6	0.5 (0.0; 0.9)	2004-2022
Brussels	N	32	45	39	37	32	36	45	38	40	42	40	46	40	31	40	37	27	46	44		
	CR	6.2	8.6	7.4	6.9	5.9	6.5	8.0	6.6	6.8	7.1	6.7	7.6	6.6	5.1	6.5	6.0	4.4	7.4	7.1		
	ESR2013	6.3	9.2	7.8	7.3	6.5	7.1	9.0	8.0	8.1	8.0	8.5	9.2	8.2	5.7	8.3	7.0	5.2	8.6	8.3	-0.1 (-1.6; 1.3)	2004-2022
Flanders	N	245	266	254	257	292	274	286	281	295	289	303	288	286	283	298	291	314	320	322		
	CR	8.0	8.7	8.2	8.3	9.4	8.7	9.0	8.8	9.2	8.9	9.3	8.8	8.7	8.6	9.0	8.7	9.4	9.5	9.5		
	ESR2013	7.9	8.5	8.1	7.9	8.8	8.1	8.4	8.2	8.4	8.0	8.1	7.6	7.5	7.5	7.7	7.4	8.0	8.1	7.8	-0.4 (-0.8; -0.1)	2004-2022
Wallonia	N	117	140	98	127	158	157	147	154	159	150	164	177	182	154	188	187	189	206	204		
	CR	6.7	8.0	5.6	7.2	8.9	8.8	8.2	8.5	8.7	8.2	8.9	9.6	9.9	8.3	10.1	10.1	10.1	11.1	10.9		
	ESR2013	6.7	7.9	5.7	7.0	8.5	8.2	7.8	8.1	8.2	7.5	8.4	9.1	9.3	7.7	9.4	9.2	9.4	10.4	10.0	2.1 (1.3; 3.0)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.2. Bladder cancer incidence trends: by tumour stage

2.2.1. Bladder cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females								
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period		
I	N	919	992	924	1,083	1,117			194	196	201	229	231			
	CR	16.4	17.6	16.3	19.1	19.6			3.4	3.4	3.4	3.9	3.9			
	ESR2013		18.8	20.1	18.3	21.2	21.5	1.6 (1.0; 2.1)	2004-2022	3.1	3.1	3.2	3.6	3.4	1.9 (1.0; 2.8)	2004-2022
								3.7 (2.3; 5.2)	2004-2011						5.3 (2.1; 8.5)	2004-2010
							-1.5 (-3.6; 0.7)	2012-2015						-0.4 (-4.2; 3.5)	2011-2014	
							1.1 (-0.3; 2.6)	2016-2022						0.6 (-1.5; 2.7)	2015-2022	
II	N	422	443	448	488	480			139	134	155	147	150			
	CR	7.5	7.9	7.9	8.6	8.4			2.4	2.3	2.7	2.5	2.6			
	ESR2013		8.8	9.1	9.0	9.7	9.4	-0.1 (-0.9; 0.6)	2004-2022	2.1	2.0	2.3	2.2	2.2	-0.1 (-1.1; 0.9)	2004-2022
								1.0 (-0.2; 2.3)	2004-2014							
							-7.3 (-10.2; -4.3)	2015-2018								
							4.5 (0.4; 8.8)	2019-2022								
III	N	264	287	253	315	268			94	110	99	104	101			
	CR	4.7	5.1	4.5	5.5	4.7			1.6	1.9	1.7	1.8	1.7			
	ESR2013		5.4	5.7	4.9	6.2	5.2	1.7 (0.3; 3.0)	2004-2022	1.5	1.8	1.6	1.7	1.6	5.0 (3.6; 6.5)	2004-2022
								-0.9 (-3.5; 1.7)	2004-2014						2.1 (-0.6; 4.9)	2004-2014
							5.0 (1.5; 8.7)	2015-2022						8.8 (5.1; 12.6)	2015-2022	
IV	N	127	143	172	159	147			51	49	56	72	64			
	CR	2.3	2.5	3.0	2.8	2.6			0.9	0.8	1.0	1.2	1.1			
	ESR2013	2.5	2.9	3.4	3.1	2.8	-1.5 (-2.9; -0.1)	2004-2022	0.8	0.8	0.9	1.1	1.0	0.8 (-1.0; 2.6)	2004-2022	

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
						3.0 (-0.1; 6.2)	2004-2013								
						-5.8 (-8.7; -2.9)	2014-2022								
X/NA	N	124	84	57	60	54		48	26	19	20	24			
	CR	2.2	1.5	1.0	1.1	0.9		0.8	0.4	0.3	0.3	0.4			
	ESR2013	2.7	1.9	1.1	1.2	1.1	-10.4 (-12.7; -8.1)	2004-2022	0.7	0.4	0.3	0.3	0.3	-8.5 (-10.8; -6.2)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3. Bladder cancer incidence trends: by age group

2.3.1. Bladder cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
15-59 N	236	223	232	232	202	216	210	223	204	209	203	194	219	185	192	170	157	184	171			
CR	7.4	7.0	7.2	7.2	6.2	6.6	6.4	6.7	6.1	6.3	6.1	5.8	6.6	5.5	5.8	5.1	4.7	5.5	5.1			
ESR2013	8.0	7.4	7.6	7.5	6.5	6.9	6.6	6.9	6.2	6.3	6.1	5.8	6.5	5.4	5.6	5.0	4.6	5.3	4.9	-2.6 (-3.1; -2.1)	2004-2022	
60-74 N	671	684	638	700	665	682	745	729	721	774	774	778	754	746	769	796	799	883	854			
CR	98.6	99.9	92.9	100.0	93.3	93.8	100.5	96.4	93.7	98.8	97.1	95.7	90.6	87.1	87.5	88.6	87.1	94.5	90.3			
ESR2013	97.8	99.2	92.8	101.3	95.2	96.5	103.8	100.0	98.1	102.6	101.5	100.8	95.6	90.4	89.9	91.0	89.1	96.5	92.8	-0.3 (-0.7; 0.1)	2004-2022	
																				0.7 (-0.3; 1.6)	2004-2012	
																					-1.8 (-3.5; -0.1)	2013-2016
																					-0.5 (-1.9; 0.8)	2017-2022
75+ N	745	719	737	751	838	833	820	880	925	904	933	915	888	934	895	983	898	1,038	1,041			
CR	254.1	237.5	234.7	230.5	248.8	241.1	231.6	243.6	250.6	240.4	243.3	233.7	224.9	236.6	225.3	243.3	217.2	249.5	241.4			
ESR2013	270.1	245.0	243.5	236.0	252.2	250.7	242.5	249.9	253.4	244.0	250.7	235.3	224.6	236.7	223.4	241.6	216.3	248.1	241.7	-0.5 (-0.9; -0.1)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Bladder cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
15-59 N	42	54	57	38	63	57	56	55	49	52	53	53	58	61	57	48	57	54	58		
CR	1.3	1.7	1.8	1.2	2.0	1.8	1.7	1.7	1.5	1.6	1.6	1.6	1.8	1.9	1.7	1.5	1.7	1.6	1.8		
ESR2013	1.4	1.8	1.9	1.2	2.0	1.8	1.8	1.7	1.5	1.6	1.6	1.6	1.7	1.8	1.7	1.4	1.7	1.6	1.7	0.0 (-1.0; 1.0)	2004-2022
60-74 N	134	161	127	140	145	136	162	158	165	137	155	163	163	140	170	188	200	212	175		
CR	17.3	20.8	16.5	18.0	18.4	17.0	20.0	19.2	19.8	16.2	18.1	18.7	18.3	15.3	18.1	19.6	20.5	21.3	17.4		
ESR2013	16.8	20.1	16.1	17.8	18.5	17.3	20.2	19.6	20.1	16.2	18.8	19.0	18.7	15.5	18.3	19.7	20.6	21.5	17.6	0.4 (-0.4; 1.2)	2004-2022
75+ N	218	236	207	243	273	273	259	259	280	292	298	295	287	266	299	279	273	306	337		
CR	41.9	44.4	38.0	43.6	47.9	47.2	44.1	43.7	46.7	48.3	48.8	47.8	46.6	43.4	48.9	45.4	44.0	49.4	53.2		
ESR2013	41.5	44.5	38.5	43.1	47.1	46.1	43.2	43.3	45.7	46.9	46.7	46.2	44.5	42.2	47.8	43.1	43.0	48.0	51.8	0.6 (0.1; 1.1)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



3.1. Bladder cancer prevalence: by region

3.1.1. *Bladder cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	N	1,818	6,290	9,545	11,389	447	1,529	2,293	2,820
	CR	31.6	109.2	165.7	198	7.5	25.8	38.6	48
	ESR2013	34.2	118.8	181.1	216.9	6.7	23.2	34.6	42.2
Brussels	N	122	402	623	739	34	104	165	208
	CR	20.1	66.1	102.4	121.5	5.4	16.4	26.1	32.9
	ESR2013	34.0	110.3	171.3	204.9	6.2	19.8	31.6	39.5
Flanders	N	1,059	3,784	5,743	6,930	254	890	1,343	1,674
	CR	31.6	112.9	171.3	206.7	7.4	26.0	39.2	48.9
	ESR2013	31.5	113.0	172.1	208.3	6.1	22.0	33.1	40.9
Wallonia	N	637	2,104	3,179	3,720	159	535	785	938
	CR	35.4	116.8	176.5	206.6	8.5	28.4	41.7	49.9
	ESR2013	40.1	131.9	200.9	236.1	7.8	26.2	38.2	45.3



4.1. Bladder cancer survival: by region

4.1.1. Bladder cancer survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	24,326	78.3% (77.7%; 78.9%)	62.6% (61.9%; 63.4%)	56.3% (55.3%; 57.3%)	49.6% (46.6%; 52.7%)
Males						
Belgium	All ages	19,160	80.6% (80.0%; 81.3%)	64.7% (63.8%; 65.6%)	58.2% (57.0%; 59.3%)	51.5% (48.1%; 55.1%)
	15-59	1,872	88.5% (87.0%; 90.0%)	77.0% (75.0%; 79.1%)	72.3% (70.1%; 74.7%)	64.3% (61.0%; 67.7%)
	60-74	7,895	86.1% (85.3%; 86.9%)	71.8% (70.7%; 73.0%)	65.4% (64.1%; 66.8%)	56.5% (54.2%; 58.9%)
	75+	9,395	74.5% (73.5%; 75.6%)	56.2% (54.8%; 57.7%)	49.2% (47.3%; 51.2%)	44.6% (38.3%; 51.9%)
Brussels	All ages	1,379	76.2% (73.7%; 78.8%)	60.1% (56.9%; 63.4%)	52.4% (48.4%; 56.7%)	39.9% (32.6%; 48.7%)
	15-59	195	86.6% (81.9%; 91.6%)	77.7% (71.7%; 84.1%)	74.4% (67.8%; 81.6%)	60.2% (48.7%; 74.5%)
	60-74	551	81.5% (78.1%; 85.0%)	63.3% (58.9%; 68.0%)	55.7% (50.7%; 61.2%)	44.3% (36.1%; 54.3%)
	75+	633	68.5% (64.4%; 72.8%)	52.0% (46.8%; 57.7%)	42.7% (36.1%; 50.6%)	30.1% (18.9%; 47.9%)
Flanders	All ages	11,266	82.0% (81.2%; 82.8%)	65.4% (64.2%; 66.5%)	59.1% (57.7%; 60.6%)	53.3% (49.0%; 57.9%)
	15-59	917	89.8% (87.8%; 91.8%)	78.3% (75.6%; 81.2%)	74.3% (71.2%; 77.5%)	68.4% (64.2%; 72.8%)
	60-74	4,409	88.0% (87.0%; 89.0%)	73.8% (72.4%; 75.3%)	67.9% (66.2%; 69.7%)	59.5% (56.6%; 62.6%)
	75+	5,942	76.3% (75.0%; 77.6%)	57.1% (55.3%; 58.9%)	50.3% (47.9%; 52.7%)	46.2% (38.9%; 54.9%)
Wallonia	All ages	6,515	79.3% (78.1%; 80.4%)	64.5% (63.0%; 66.1%)	57.7% (55.8%; 59.7%)	50.9% (44.7%; 58.0%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	15-59	760	87.4% (85.0%; 89.9%)	75.3% (72.1%; 78.6%)	69.5% (65.9%; 73.3%)	60.3% (55.1%; 66.0%)
	60-74	2,935	84.1% (82.7%; 85.5%)	70.5% (68.6%; 72.4%)	63.6% (61.3%; 65.9%)	54.4% (50.4%; 58.6%)
	75+	2,820	72.1% (70.1%; 74.1%)	55.4% (52.7%; 58.1%)	48.4% (44.8%; 52.3%)	44.5% (32.6%; 60.6%)
Females						
Belgium	All ages	5,166	69.5% (68.1%; 70.9%)	55.0% (53.4%; 56.7%)	49.2% (47.2%; 51.3%)	42.3% (36.9%; 48.5%)
	15-59	549	78.8% (75.4%; 82.3%)	66.3% (62.3%; 70.5%)	61.2% (57.0%; 65.7%)	59.1% (54.4%; 64.1%)
	60-74	1,696	80.5% (78.6%; 82.5%)	66.6% (64.2%; 69.1%)	61.3% (58.7%; 64.1%)	53.5% (49.4%; 57.9%)
	75+	2,921	61.3% (59.4%; 63.3%)	46.1% (43.8%; 48.5%)	39.8% (36.9%; 43.0%)	32.4% (24.0%; 43.8%)
Brussels	All ages	390	69.9% (65.1%; 75.1%)	51.4% (45.7%; 57.7%)	46.6% (40.2%; 53.9%)	48.7% (39.0%; 60.9%)
	15-59	50	67.6% (55.8%; 82.0%)	59.6% (47.3%; 75.2%)	57.6% (45.0%; 73.7%)	54.0% (39.8%; 73.2%)
	60-74	117	80.6% (73.5%; 88.3%)	62.2% (53.4%; 72.5%)	56.2% (46.6%; 67.7%)	48.1% (35.4%; 65.4%)
	75+	223	64.8% (58.1%; 72.3%)	44.0% (36.4%; 53.2%)	39.2% (30.5%; 50.5%)	51.2% (35.2%; 74.5%)
Flanders	All ages	2,983	70.4% (68.6%; 72.2%)	55.9% (53.8%; 58.1%)	50.2% (47.6%; 52.9%)	40.9% (33.4%; 50.2%)
	15-59	279	81.5% (77.1%; 86.3%)	67.8% (62.5%; 73.7%)	63.8% (58.1%; 70.0%)	61.7% (55.6%; 68.5%)
	60-74	935	81.8% (79.3%; 84.4%)	68.1% (65.0%; 71.4%)	61.5% (58.0%; 65.3%)	54.3% (49.1%; 60.1%)
	75+	1,769	62.6% (60.1%; 65.1%)	47.6% (44.6%; 50.7%)	42.0% (38.3%; 45.9%)	30.3% (19.7%; 46.7%)
Wallonia	All ages	1,793	67.9% (65.6%; 70.3%)	54.2% (51.5%; 57.0%)	48.1% (44.5%; 51.9%)	43.1% (35.6%; 52.1%)
	15-59	220	77.8% (72.4%; 83.5%)	65.9% (59.8%; 72.7%)	58.6% (51.9%; 66.2%)	56.9% (49.4%; 65.5%)
	60-74	644	78.7% (75.5%; 82.0%)	65.2% (61.3%; 69.3%)	62.0% (57.7%; 66.5%)	53.3% (46.4%; 61.2%)
	75+	929	58.1% (54.8%; 61.8%)	43.8% (39.8%; 48.2%)	35.8% (30.3%; 42.3%)	32.7% (20.8%; 51.5%)

4.2. Bladder cancer survival: by tumour stage

4.2.1. Bladder cancer survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

cStage	Net Survival Probability, 2013-2022						
	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	24,326	78.3% (77.7%; 78.9%)	68.2% (67.5%; 68.9%)	62.6% (61.9%; 63.4%)	59.0% (58.1%; 59.9%)	56.3% (55.3%; 57.3%)	49.6% (46.6%; 52.7%)
Males							
All	19,160	80.6% (80.0%; 81.3%)	70.6% (69.8%; 71.4%)	64.7% (63.8%; 65.6%)	61.0% (60.0%; 62.0%)	58.2% (57.0%; 59.3%)	51.5% (48.1%; 55.1%)
I	4,013	94.4% (93.3%; 95.4%)	88.1% (86.7%; 89.6%)	83.5% (81.6%; 85.4%)	79.7% (77.4%; 82.0%)	76.4% (73.5%; 79.4%)	75.2% (67.5%; 83.8%)
II	3,287	76.3% (74.7%; 78.0%)	62.6% (60.6%; 64.5%)	55.5% (53.3%; 57.7%)	52.0% (49.7%; 54.4%)	48.7% (46.1%; 51.4%)	35.2% (29.2%; 42.5%)
III	1,311	65.9% (63.1%; 68.7%)	49.5% (46.6%; 52.7%)	42.9% (39.8%; 46.2%)	39.4% (36.1%; 43.1%)	38.0% (34.4%; 42.0%)	38.8% (30.3%; 49.9%)
IV	1,387	40.1% (37.5%; 42.8%)	24.2% (21.9%; 26.7%)	17.9% (15.8%; 20.3%)	15.9% (13.8%; 18.3%)	13.8% (11.7%; 16.3%)	11.4% (8.6%; 15.1%)
X/NA	9,185	84.4% (83.5%; 85.3%)	75.7% (74.6%; 76.8%)	69.9% (68.7%; 71.2%)	66.0% (64.6%; 67.5%)	63.1% (61.5%; 64.8%)	55.7% (51.0%; 60.8%)
Females							
All	5,166	69.5% (68.1%; 70.9%)	59.2% (57.7%; 60.7%)	55.0% (53.4%; 56.7%)	51.4% (49.6%; 53.3%)	49.2% (47.2%; 51.3%)	42.3% (36.9%; 48.5%)
I	883	91.1% (88.8%; 93.5%)	86.2% (83.2%; 89.3%)	82.0% (78.3%; 85.9%)	79.6% (75.1%; 84.4%)	75.4% (70.0%; 81.2%)	65.6% (45.0%; 95.6%)
II	1,006	68.0% (64.9%; 71.2%)	52.6% (49.2%; 56.2%)	48.7% (45.1%; 52.6%)	45.4% (41.5%; 49.7%)	42.8% (38.4%; 47.7%)	34.7% (26.3%; 46.0%)
III	538	55.4% (51.2%; 59.9%)	41.3% (37.1%; 46.0%)	35.2% (30.9%; 40.1%)	32.2% (27.7%; 37.3%)	30.3% (25.6%; 35.8%)	18.7% (11.5%; 30.3%)
IV	499	29.0% (25.2%; 33.4%)	15.9% (12.9%; 19.7%)	11.9% (9.2%; 15.5%)	9.9% (7.3%; 13.5%)	9.0% (6.4%; 12.6%)	6.2% (3.6%; 10.6%)
X/NA	2,245	74.0% (72.0%; 76.0%)	65.4% (63.1%; 67.7%)	61.5% (59.0%; 64.0%)	57.1% (54.3%; 60.0%)	55.1% (52.1%; 58.3%)	48.6% (41.7%; 56.7%)

4.2.2. Bladder cancer survival by pathological stage ((y)pStage), and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
(y)pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	24,326	78.3% (77.7%; 78.9%)	68.2% (67.5%; 68.9%)	62.6% (61.9%; 63.4%)	59.0% (58.1%; 59.9%)	56.3% (55.3%; 57.3%)	49.6% (46.6%; 52.7%)
Males							
All	19,160	80.6% (80.0%; 81.3%)	70.6% (69.8%; 71.4%)	64.7% (63.8%; 65.6%)	61.0% (60.0%; 62.0%)	58.2% (57.0%; 59.3%)	51.5% (48.1%; 55.1%)
I	9,440	94.8% (94.1%; 95.4%)	89.5% (88.6%; 90.5%)	85.4% (84.3%; 86.6%)	81.5% (80.1%; 83.0%)	78.2% (76.4%; 79.9%)	72.6% (67.1%; 78.6%)
II	3,612	69.6% (68.0%; 71.3%)	56.9% (55.0%; 58.8%)	49.7% (47.7%; 51.8%)	46.2% (44.1%; 48.4%)	43.4% (41.0%; 45.9%)	34.2% (28.2%; 41.4%)
III	2,177	72.5% (70.5%; 74.6%)	52.7% (50.4%; 55.1%)	44.6% (42.3%; 47.2%)	39.9% (37.4%; 42.6%)	36.8% (34.2%; 39.7%)	29.8% (24.6%; 36.0%)
IV	823	51.7% (48.3%; 55.4%)	31.3% (28.1%; 34.8%)	22.4% (19.5%; 25.6%)	19.5% (16.7%; 22.7%)	17.3% (14.6%; 20.5%)	13.3% (9.6%; 18.5%)
X/NA	3,142	63.9% (62.1%; 65.8%)	51.8% (49.8%; 53.8%)	44.5% (42.4%; 46.7%)	41.9% (39.7%; 44.3%)	40.9% (38.4%; 43.6%)	35.5% (28.8%; 43.8%)
Females							
All	5,166	69.5% (68.1%; 70.9%)	59.2% (57.7%; 60.7%)	55.0% (53.4%; 56.7%)	51.4% (49.6%; 53.3%)	49.2% (47.2%; 51.3%)	42.3% (36.9%; 48.5%)
I	1,996	92.4% (90.9%; 93.9%)	86.8% (84.8%; 88.8%)	83.8% (81.4%; 86.3%)	80.3% (77.4%; 83.3%)	76.4% (72.9%; 80.0%)	64.8% (53.4%; 78.5%)
II	1,095	56.4% (53.3%; 59.6%)	44.8% (41.7%; 48.3%)	41.3% (38.0%; 44.9%)	38.5% (35.1%; 42.4%)	37.6% (33.9%; 41.7%)	35.6% (27.4%; 46.1%)
III	701	70.8% (67.4%; 74.4%)	54.1% (50.3%; 58.2%)	46.4% (42.5%; 50.7%)	40.9% (36.8%; 45.5%)	38.4% (34.1%; 43.4%)	30.3% (22.5%; 40.7%)
IV	295	43.5% (38.1%; 49.7%)	23.5% (19.0%; 29.1%)	17.0% (13.0%; 22.2%)	14.6% (10.9%; 19.7%)	13.0% (9.3%; 18.1%)	8.3% (5.1%; 13.5%)
X/NA	1,086	46.6% (43.5%; 49.8%)	35.6% (32.6%; 39.0%)	31.4% (28.3%; 34.9%)	27.8% (24.0%; 32.1%)	27.4% (23.5%; 32.1%)	24.4% (19.1%; 31.2%)

4.2.3. Bladder cancer survival by stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	24,326	78.3% (77.7%; 78.9%)	68.2% (67.5%; 68.9%)	62.6% (61.9%; 63.4%)	59.0% (58.1%; 59.9%)	56.3% (55.3%; 57.3%)	49.6% (46.6%; 52.7%)
Males							
All	19,160	80.6% (80.0%; 81.3%)	70.6% (69.8%; 71.4%)	64.7% (63.8%; 65.6%)	61.0% (60.0%; 62.0%)	58.2% (57.0%; 59.3%)	51.5% (48.1%; 55.1%)
I	9,482	95.0% (94.4%; 95.7%)	89.7% (88.8%; 90.7%)	85.6% (84.4%; 86.8%)	81.7% (80.2%; 83.1%)	78.3% (76.6%; 80.1%)	72.8% (67.4%; 78.7%)
II	4,488	73.1% (71.6%; 74.5%)	60.2% (58.5%; 61.9%)	52.8% (51.0%; 54.7%)	49.4% (47.4%; 51.4%)	46.4% (44.1%; 48.7%)	36.2% (30.0%; 43.7%)
III	2,381	71.0% (69.0%; 73.0%)	52.6% (50.4%; 54.9%)	44.9% (42.6%; 47.3%)	40.3% (37.9%; 42.9%)	37.7% (35.1%; 40.5%)	30.3% (25.0%; 36.8%)
IV	1,763	43.1% (40.8%; 45.6%)	26.0% (23.9%; 28.3%)	18.8% (16.9%; 20.9%)	16.7% (14.8%; 18.8%)	15.1% (13.2%; 17.2%)	12.3% (9.5%; 16.0%)
X/NA	1,080	68.0% (64.9%; 71.1%)	56.9% (53.5%; 60.5%)	48.8% (45.2%; 52.7%)	46.2% (42.3%; 50.4%)	45.2% (41.1%; 49.8%)	39.2% (29.4%; 52.3%)
Females							
All	5,166	69.5% (68.1%; 70.9%)	59.2% (57.7%; 60.7%)	55.0% (53.4%; 56.7%)	51.4% (49.6%; 53.3%)	49.2% (47.2%; 51.3%)	42.3% (36.9%; 48.5%)
I	2,011	92.7% (91.2%; 94.2%)	87.3% (85.3%; 89.3%)	84.2% (81.8%; 86.7%)	80.6% (77.7%; 83.6%)	76.8% (73.4%; 80.4%)	65.6% (54.3%; 79.2%)
II	1,376	59.5% (56.8%; 62.4%)	47.0% (44.1%; 50.1%)	43.7% (40.7%; 46.9%)	40.0% (36.8%; 43.5%)	38.3% (34.8%; 42.2%)	35.1% (27.3%; 45.1%)
III	825	63.3% (59.9%; 66.8%)	47.9% (44.4%; 51.7%)	40.7% (37.1%; 44.6%)	36.8% (33.0%; 40.9%)	34.6% (30.7%; 39.0%)	26.8% (20.3%; 35.5%)
IV	623	33.8% (30.2%; 37.8%)	18.6% (15.7%; 22.1%)	14.0% (11.4%; 17.3%)	11.7% (9.2%; 14.9%)	11.1% (8.5%; 14.3%)	7.4% (4.9%; 11.1%)
X/NA	338	52.3% (46.9%; 58.3%)	43.1% (37.6%; 49.5%)	37.4% (31.8%; 44.0%)	33.5% (26.4%; 42.4%)	34.2% (26.8%; 43.7%)	33.2% (23.9%; 46.2%)



5.1. Bladder cancer survival trends: by tumour stage

5.1.1. Bladder cancer survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	8,865	79.4% (78.4%; 80.3%)	61.9% (60.6%; 63.1%)	55.1% (53.6%; 56.5%)	2,376	68.8% (66.8%; 70.9%)	53.4% (51.1%; 55.8%)	47.7% (45.1%; 50.5%)
	I	4,018	94.9% (93.9%; 95.9%)	83.5% (81.8%; 85.3%)	76.3% (74.1%; 78.6%)	883	90.4% (88.1%; 92.9%)	79.6% (76.0%; 83.4%)	74.0% (69.5%; 78.7%)
	II	2,202	68.2% (66.0%; 70.3%)	47.3% (44.9%; 49.9%)	40.6% (38.0%; 43.4%)	691	59.2% (55.4%; 63.3%)	41.9% (37.9%; 46.4%)	36.3% (31.9%; 41.4%)
	III	904	66.0% (62.7%; 69.4%)	40.7% (37.3%; 44.6%)	34.7% (31.1%; 38.8%)	269	57.5% (51.5%; 64.1%)	37.4% (31.5%; 44.3%)	34.4% (28.2%; 41.8%)
	IV	864	55.6% (52.2%; 59.1%)	23.3% (20.4%; 26.5%)	17.5% (14.9%; 20.6%)	277	43.0% (37.5%; 49.4%)	18.8% (14.6%; 24.2%)	12.7% (9.2%; 17.7%)
	X/NA	888	73.4% (70.3%; 76.8%)	58.4% (54.5%; 62.6%)	51.1% (46.7%; 55.9%)	261	59.5% (53.5%; 66.2%)	47.1% (40.6%; 54.7%)	39.3% (31.1%; 49.6%)
2013-2017	All	9,363	79.8% (78.9%; 80.8%)	63.3% (62.0%; 64.5%)	56.4% (54.9%; 57.8%)	2,463	68.7% (66.7%; 70.7%)	54.3% (52.0%; 56.7%)	47.4% (44.7%; 50.2%)
	I	4,462	94.5% (93.5%; 95.4%)	84.3% (82.7%; 86.0%)	76.8% (74.6%; 79.0%)	962	92.2% (90.0%; 94.4%)	83.7% (80.3%; 87.3%)	74.0% (69.4%; 78.7%)
	II	2,211	71.5% (69.4%; 73.6%)	51.3% (48.8%; 53.9%)	43.9% (41.2%; 46.9%)	652	56.2% (52.3%; 60.5%)	40.9% (36.7%; 45.5%)	35.5% (31.0%; 40.7%)
	III	994	69.8% (66.8%; 72.9%)	44.4% (41.0%; 48.0%)	36.1% (32.5%; 40.0%)	319	61.6% (56.3%; 67.4%)	40.1% (34.7%; 46.4%)	34.6% (29.0%; 41.2%)
	IV	1,015	50.0% (46.9%; 53.3%)	22.2% (19.6%; 25.1%)	18.3% (15.8%; 21.1%)	331	39.6% (34.6%; 45.4%)	16.6% (12.9%; 21.4%)	12.6% (9.2%; 17.2%)
	X/NA	702	69.7% (66.0%; 73.6%)	51.8% (47.3%; 56.7%)	48.6% (43.5%; 54.3%)	202	55.0% (48.1%; 62.9%)	41.1% (33.9%; 49.9%)	35.6% (26.0%; 48.8%)
2018-2022	All	9,802	81.4% (80.5%; 82.3%)	66.1% (64.9%; 67.4%)	60.6% (58.7%; 62.5%)	2,704	70.2% (68.3%; 72.1%)	55.6% (53.3%; 57.9%)	52.2% (49.4%; 55.2%)
	I	5,021	95.5% (94.6%; 96.4%)	86.8% (85.1%; 88.5%)	80.4% (77.6%; 83.2%)	1,049	93.1% (91.1%; 95.1%)	84.8% (81.4%; 88.3%)	82.5% (77.5%; 87.8%)
	II	2,277	74.6% (72.6%; 76.7%)	54.3% (51.7%; 57.1%)	49.8% (46.0%; 54.0%)	724	62.5% (58.8%; 66.5%)	46.1% (41.9%; 50.7%)	41.5% (36.5%; 47.2%)

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	1,387	71.9% (69.3%; 74.5%)	45.3% (42.2%; 48.6%)	40.1% (36.3%; 44.3%)	506	64.3% (60.1%; 68.9%)	40.9% (36.2%; 46.2%)	34.1% (28.7%; 40.4%)
	IV	748	33.8% (30.5%; 37.4%)	14.0% (11.4%; 17.2%)	9.7% (6.7%; 14.0%)	292	27.2% (22.5%; 33.0%)	11.0% (7.6%; 15.9%)	10.7% (7.2%; 15.8%)
	X/NA	378	64.8% (59.6%; 70.4%)	43.0% (37.1%; 49.9%)	38.0% (31.3%; 46.3%)	136	48.3% (40.2%; 58.0%)	31.7% (23.7%; 42.5%)	33.1% (23.8%; 45.9%)

6. CANCER MORTALITY



6.1. Bladder cancer mortality: by region

6.1.1. Bladder cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
Belgium	0	0	0	0	0	0	0	0	0	1	6	16	23	45	82	73	105	106	64	14	535	11.2
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.5]	[4.0]	[6.3]	[14.7]	[30.9]	[41.9]	[80.4]	[136.4]	[228.0]	[256.7]	[9.4]	(10.2; 12.2)
Brussels	0	0	0	0	0	0	0	0	0	0	1	1	1	3	6	4	6	9	4	0	35	10.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.5]	[2.9]	[3.7]	[14.4]	[35.9]	[34.8]	[71.0]	[178.1]	[183.9]	[0.0]	[5.8]	(7.0; 14.0)
Flanders	0	0	0	0	0	0	0	0	0	1	4	8	13	27	44	46	64	72	35	9	323	10.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.7]	[3.3]	[5.9]	[14.4]	[27.2]	[40.3]	[74.2]	[139.3]	[191.0]	[251.3]	[9.8]	(9.3; 11.6)
Wallonia	0	0	0	0	0	0	0	0	0	0	1	7	9	15	32	23	35	25	25	5	177	13.1
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[5.6]	[7.8]	[15.3]	[37.0]	[47.4]	[97.4]	[119.4]	[329.9]	[355.6]	[9.9]	(11.1; 15.1)
Females																						
Belgium	0	0	0	0	0	0	0	0	3	2	2	4	9	16	15	21	44	44	30	15	205	2.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.5]	[0.5]	[1.0]	[2.4]	[4.9]	[5.1]	[9.8]	[23.8]	[32.5]	[45.3]	[78.0]	[3.5]	(2.5; 3.3)
Brussels	0	0	0	0	0	0	0	0	0	1	0	0	2	0	0	0	1	3	0	1	8	1.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.5]	[0.0]	[0.0]	[6.7]	[0.0]	[0.0]	[0.0]	[7.3]	[29.5]	[0.0]	[51.1]	[1.3]	(0.4; 2.2)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	0	0	1	0	2	2	4	7	6	14	24	33	21	10	124	2.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[0.9]	[0.8]	[1.8]	[3.6]	[3.4]	[10.5]	[20.7]	[38.8]	[52.4]	[89.0]	[3.7]	(2.3; 3.2)
Wallonia	0	0	0	0	0	0	0	0	2	1	0	2	3	9	9	7	19	8	9	4	73	3.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[1.7]	[0.8]	[0.0]	[1.6]	[2.5]	[8.3]	[8.9]	[11.0]	[34.4]	[20.0]	[44.1]	[66.2]	[3.9]	(2.6; 4.2)

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Wallonia N	203	217	202	186	217	192	217	228	244	207	202	232	189	209	182	192	197	177		
CR	12.4	13.2	12.2	11.2	12.9	11.4	12.8	13.3	14.1	11.9	11.6	13.3	10.8	11.8	10.3	10.8	11.1	9.9		
ESR2013	18.7	21.5	19.4	18.1	18.5	16.3	18.1	19.6	19.9	16.4	16.1	18.1	14.3	16.3	13.7	14.5	14.2	13.1	-2.2 (-3.0; -1.5)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Bladder cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	N	197	213	231	215	229	245	252	225	232	239	235	252	233	245	223	215	197	205			
	CR	3.7	4.0	4.3	4.0	4.2	4.5	4.6	4.0	4.1	4.2	4.1	4.4	4.1	4.3	3.9	3.7	3.4	3.5			
	ESR2013	3.6	3.9	4.2	3.8	3.9	4.1	4.2	3.7	3.8	3.7	3.5	3.8	3.6	3.6	3.2	3.0	2.7	2.9	-1.8 (-2.3; -1.3)	2004-2021	
																				0.4 (-0.9; 1.7)	2004-2012	
																					-3.7 (-4.8; -2.6)	2013-2021
Brussels	N	18	19	31	28	25	20	24	19	24	18	21	19	20	22	17	24	15	8			
	CR	3.5	3.6	5.9	5.2	4.6	3.6	4.3	3.3	4.1	3.0	3.5	3.2	3.3	3.6	2.8	3.9	2.4	1.3			
	ESR2013	3.0	3.7	5.7	5.3	4.9	3.6	4.2	3.0	4.9	3.1	3.4	3.6	3.6	3.9	3.0	3.8	2.3	1.3	-3.5 (-6.0; -1.0)	2004-2021	
																					0.8 (-5.2; 7.2)	2004-2012
																					-7.3 (-12.1; -2.1)	2013-2021
Flanders	N	123	129	133	119	134	143	137	137	122	138	144	146	137	130	131	114	107	124			
	CR	4.0	4.2	4.3	3.8	4.3	4.5	4.3	4.3	3.8	4.3	4.4	4.5	4.2	3.9	4.0	3.4	3.2	3.7			
	ESR2013	4.0	4.1	4.2	3.7	3.9	4.2	3.9	3.8	3.4	3.6	3.7	3.6	3.5	3.1	3.1	2.7	2.4	2.7	-2.9 (-3.4; -2.4)	2004-2021	
																					-1.2 (-2.1; -0.3)	2004-2015
																					-5.9 (-7.5; -4.2)	2016-2021
Wallonia	N	56	65	67	68	70	82	91	69	86	83	70	87	76	93	75	77	75	73			
	CR	3.2	3.7	3.8	3.8	3.9	4.6	5.1	3.8	4.7	4.5	3.8	4.7	4.1	5.0	4.0	4.1	4.0	3.9			
	ESR2013	3.1	3.6	3.7	3.6	3.5	4.2	4.7	3.5	4.4	3.8	3.3	4.1	3.7	4.2	3.5	3.4	3.3	3.4	0.3 (-0.6; 1.2)	2004-2021	
																					4.3 (1.3; 7.3)	2004-2010
																					-1.8 (-3.2; -0.4)	2011-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024